Wuhan YZY Biopharma Co Ltd

02496

Company Profile

  • Business description

    Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).

  • Contact

    No. 666 Gaoxin Road
    Building C2-1, Guanggu Biocity
    East Lake High Tech Development Zone
    Hubei Province
    Wuhan
    CHN

    T: +86 2782668988

    http://www.yzybio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    106

Stocks News & Analysis

stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.
stocks

Coca-Cola earnings: Innovation and brand strength underpin growth

We plan to raise our fair value estimate of Coca-Cola stock.
stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,321.1010.80-0.12%
CAC 408,209.2249.64-0.60%
DAX 4024,235.1194.92-0.39%
Dow JONES (US)46,924.74218.160.47%
FTSE 1009,496.9569.960.74%
HKSE25,781.77245.78-0.94%
NASDAQ22,953.6736.88-0.16%
Nikkei 22549,307.798.27-0.02%
NZX 50 Index13,306.4471.41-0.53%
S&P 5006,735.350.220.00%
S&P/ASX 2009,030.0010.30-0.11%
SSE Composite Index3,913.762.57-0.07%

Market Movers